A BILL 
To amend title XIX of the Social Security Act to improve 
transparency and prevent the use of abusive spread pric-
ing and related practices in the Medicaid program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Drug Price Trans-
4
parency in Medicaid Act of 2021’’. 
5
SEC. 2. IMPROVING TRANSPARENCY AND PREVENTING THE 
6
USE OF ABUSIVE SPREAD PRICING AND RE-
7
LATED PRACTICES IN MEDICAID. 
8
(a) PASS-THROUGH PRICING REQUIRED.— 
9
06:56 Dec 09, 2021
H6101
2 
•HR 6101 IH
(1) IN GENERAL.—Section 1927(e) of the So-
1
cial Security Act (42 U.S.C. 1396r–8(e)) is amended 
2
by adding at the end the following: 
3
‘‘(6) PASS-THROUGH
PRICING
REQUIRED.—A 
4
contract between the State and a pharmacy benefit 
5
manager (referred to in this paragraph as a ‘PBM’), 
6
or a contract between the State and a managed care 
7
entity or other specified entity (as such terms are 
8
defined in section 1903(m)(9)(D)) that includes pro-
9
visions making the entity responsible for coverage of 
10
covered outpatient drugs dispensed to individuals en-
11
rolled with the entity, shall require that payment for 
12
such drugs and related administrative services (as 
13
applicable), including payments made by a PBM on 
14
behalf of the State or entity, is based on a pass- 
15
through pricing model under which— 
16
‘‘(A) any payment made by the entity or 
17
the PBM (as applicable) for such a drug— 
18
‘‘(i) is limited to— 
19
‘‘(I) ingredient cost; and 
20
‘‘(II) a professional dispensing 
21
fee that is not less than the profes-
22
sional dispensing fee that the State 
23
plan or waiver would pay if the plan 
24
06:56 Dec 09, 2021
H6101
3 
•HR 6101 IH
or waiver was making the payment di-
1
rectly; 
2
‘‘(ii) is passed through in its entirety 
3
by the entity or PBM to the pharmacy or 
4
provider that dispenses the drug; and 
5
‘‘(iii) is made in a manner that is con-
6
sistent with section 1902(a)(30)(A) and 
7
sections 447.512, 447.514, and 447.518 of 
8
title 42, Code of Federal Regulations (or 
9
any successor regulation) as if such re-
10
quirements applied directly to the entity or 
11
the PBM, except that any payment by the 
12
entity or the PBM (as applicable) for the 
13
ingredient cost of a covered outpatient 
14
drug dispensed by providers and phar-
15
macies referenced in clauses (i) or (ii) of 
16
section 447.518(a)(1) of title 42, Code of 
17
Federal Regulations (or any successor reg-
18
ulation) shall be the same as the payment 
19
amount for the ingredient cost when dis-
20
pensed by providers and pharmacies not 
21
referenced in such clauses, and in no case 
22
shall payment for the ingredient cost of a 
23
covered outpatient drug be based on the 
24
actual acquisition cost of a drug dispensed 
25
06:56 Dec 09, 2021
H6101
4 
•HR 6101 IH
by providers and pharmacies referenced in 
1
such clauses or take into account a drug’s 
2
status as a drug purchased at a discounted 
3
price by a provider or pharmacy referenced 
4
in such clauses; 
5
‘‘(B) payment to the entity or the PBM 
6
(as applicable) for administrative services per-
7
formed by the entity or PBM is limited to a 
8
reasonable administrative fee that covers the 
9
reasonable cost of providing such services; 
10
‘‘(C) the entity or the PBM (as applicable) 
11
shall make available to the State, and the Sec-
12
retary upon request, all costs and payments re-
13
lated to covered outpatient drugs and accom-
14
panying administrative services incurred, re-
15
ceived, or made by the entity or the PBM, in-
16
cluding ingredient costs, professional dispensing 
17
fees, administrative fees, post-sale and post-in-
18
voice fees, discounts, or related adjustments 
19
such as direct and indirect remuneration fees, 
20
and any and all other remuneration; and 
21
‘‘(D) any form of spread pricing whereby 
22
any amount charged or claimed by the entity or 
23
the PBM (as applicable) is in excess of the 
24
amount paid to the pharmacies on behalf of the 
25
06:56 Dec 09, 2021
H6101
5 
•HR 6101 IH
entity, including any post-sale or post-invoice 
1
fees, discounts, or related adjustments such as 
2
direct and indirect remuneration fees or assess-
3
ments (after allowing for a reasonable adminis-
4
trative fee as described in subparagraph (B)) is 
5
not allowable for purposes of claiming Federal 
6
matching payments under this title. 
7
‘‘(7) PROTECTION AGAINST MANDATES RELAT-
8
ING TO USE OF 340B DRUGS.— 
9
‘‘(A) IN GENERAL.—Notwithstanding any 
10
other provision of law, no State, Medicaid man-
11
aged care organization (as defined in section 
12
1903(m)(1)(A)), or pharmacy benefit manager 
13
may prohibit a covered entity under section 
14
340B of the Public Health Service Act, or a 
15
pharmacy under contract with a covered entity 
16
to dispense drugs on behalf of the covered enti-
17
ty, from dispensing covered outpatient drugs 
18
purchased under such section to individuals re-
19
ceiving benefits under this title and from receiv-
20
ing payment in accordance with this section, or 
21
require that such covered entity or pharmacy 
22
dispense covered outpatient drugs purchased 
23
under section 340B to such individuals. 
24
06:56 Dec 09, 2021
H6101
6 
•HR 6101 IH
‘‘(B) NOTIFICATION.—The Secretary shall 
1
notify States that States may not prohibit a 
2
provider under this title that is a covered entity 
3
under section 340B of the Public Health Serv-
4
ices Act, or a pharmacy under contract with a 
5
covered entity, from submitting claims for reim-
6
bursement for drugs purchased under such sec-
7
tion that are dispensed to individuals receiving 
8
benefits under this title and may not require 
9
such provider to dispense covered outpatient 
10
drugs purchased under such section to such in-
11
dividuals.’’. 
12
(2) 
CONFORMING
AMENDMENT.—Section 
13
1903(m)(2)(A)(xiii) 
of 
such 
Act 
(42 
U.S.C. 
14
1396b(m)(2)(A)(xiii)) is amended— 
15
(A) by striking ‘‘and (III)’’ and inserting 
16
‘‘(III)’’; 
17
(B) by inserting before the period at the 
18
end the following: ‘‘, and (IV) pharmacy benefit 
19
management services provided by the entity, or 
20
provided by a pharmacy benefit manager on be-
21
half of the entity under a contract or other ar-
22
rangement between the entity and the phar-
23
macy benefit manager, shall comply with the re-
24
quirements of section 1927(e)(6)’’; and 
25
06:56 Dec 09, 2021
H6101
7 
•HR 6101 IH
(C) by moving the left margin 2 ems to the 
1
left. 
2
(3) EFFECTIVE DATE.—The amendments made 
3
by this subsection apply to contracts between States 
4
and managed care entities, other specified entities, 
5
or pharmacy benefits managers that are entered into 
6
or renewed on or after the date that is 18 months 
7
after the date of enactment of this Act. 
8
(b) ENSURING ACCURATE PAYMENTS
TO PHAR-
9
MACIES UNDER MEDICAID.— 
10
(1) IN GENERAL.—Section 1927(f) of the Social 
11
Security Act (42 U.S.C. 1396r–8(f)) is amended— 
12
(A) by striking ‘‘and’’ after the semicolon 
13
at the end of paragraph (1)(A)(i) and all that 
14
precedes it through ‘‘(1)’’ and inserting the fol-
15
lowing: 
16
‘‘(1) DETERMINING PHARMACY ACTUAL ACQUI-
17
SITION COSTS.—The Secretary shall conduct a sur-
18
vey of retail community pharmacy drug prices to de-
19
termine the national average drug acquisition cost as 
20
follows: 
21
‘‘(A) USE
OF
VENDOR.—The Secretary 
22
may contract services for— 
23
‘‘(i) with respect to retail community 
24
pharmacies, the determination of retail 
25
06:56 Dec 09, 2021
H6101
8 
•HR 6101 IH
survey prices of the national average drug 
1
acquisition cost for covered outpatient 
2
drugs based on a monthly survey of such 
3
pharmacies, net of all discounts and re-
4
bates (to the extent any information with 
5
respect to such discounts and rebates is 
6
available); and’’; 
7
(B) by adding at the end of paragraph (1) 
8
the following: 
9
‘‘(F) SURVEY
REPORTING.—In order to 
10
meet the requirement of section 1902(a)(54), a 
11
State shall require that any retail community 
12
pharmacy in the State that receives any pay-
13
ment, reimbursement, administrative fee, dis-
14
count, or rebate related to the dispensing of 
15
covered outpatient drugs to individuals receiv-
16
ing benefits under this title, regardless of 
17
whether such payment, fee, discount, or rebate 
18
is received from the State or a managed care 
19
entity directly or from a pharmacy benefit man-
20
ager or another entity that has a contract with 
21
the State or a managed care entity, shall re-
22
spond to surveys of retail prices conducted 
23
under this subsection. 
24
06:56 Dec 09, 2021
H6101
9 
•HR 6101 IH
‘‘(G) SURVEY INFORMATION.—Information 
1
on retail community actual acquisition prices 
2
obtained under this paragraph shall be made 
3
publicly available and shall include at least the 
4
following: 
5
‘‘(i) The monthly response rate of the 
6
survey including a list of pharmacies not in 
7
compliance with subparagraph (F). 
8
‘‘(ii) The sampling frame and number 
9
of pharmacies sampled monthly. 
10
‘‘(iii) 
Characteristics 
of 
reporting 
11
pharmacies, including type (such as inde-
12
pendent or chain), geographic or regional 
13
location, and dispensing volume. 
14
‘‘(iv) Reporting of a separate national 
15
average drug acquisition cost for each drug 
16
for independent retail pharmacies and 
17
chain pharmacies. 
18
‘‘(v) Information on price concessions 
19
including on and off invoice discounts, re-
20
bates, and other price concessions to the 
21
extent that such information is available 
22
during the survey period. 
23
‘‘(vi) Information on average profes-
24
sional dispensing fees paid. 
25
06:56 Dec 09, 2021
H6101
10 
•HR 6101 IH
‘‘(H) 
REPORT
ON
SPECIALTY
PHAR-
1
MACIES.— 
2
‘‘(i) IN GENERAL.—Not later than 1 
3
year after the effective date of this sub-
4
paragraph, the Secretary shall submit a re-
5
port to Congress examining specialty drug 
6
coverage and reimbursement under this 
7
title. 
8
‘‘(ii) CONTENT OF REPORT.—Such re-
9
port shall include a description of how 
10
State Medicaid programs define specialty 
11
drugs, how much State Medicaid programs 
12
pay for specialty drugs, how States and 
13
managed care plans determine payment for 
14
specialty drugs, the settings in which spe-
15
cialty drugs are dispensed (such as retail 
16
community pharmacies or specialty phar-
17
macies), whether acquisition costs for spe-
18
cialty drugs are captured in the national 
19
average drug acquisition cost survey, and 
20
recommendations as to whether specialty 
21
pharmacies should be included in the sur-
22
vey of retail prices to ensure national aver-
23
age drug acquisition costs capture drugs 
24
06:56 Dec 09, 2021
H6101
11 
•HR 6101 IH
sold at specialty pharmacies and how such 
1
specialty pharmacies should be defined.’’; 
2
(C) in paragraph (2)— 
3
(i) in subparagraph (A), by inserting 
4
‘‘, including payments rates under Med-
5
icaid managed care plans,’’ after ‘‘under 
6
this title’’; and 
7
(ii) in subparagraph (B), by inserting 
8
‘‘and the basis for such dispensing fees’’ 
9
before the semicolon; and 
10
(D) in paragraph (4), by inserting ‘‘, and 
11
$5,000,000 for fiscal year 2023 and each fiscal 
12
year thereafter,’’ after ‘‘2010’’. 
13
(2) EFFECTIVE DATE.—The amendments made 
14
by this subsection take effect on the first day of the 
15
first quarter that begins on or after the date that is 
16
18 months after the date of enactment of this Act. 
17
Æ 
06:56 Dec 09, 2021
H6101
